As the details in the TPP agreement become known, the worries mount.The BATR RealPolitik Newsletter October 8, 2015 edition, TPP DeceitfulDeal is Done, has a number of significant articles on the TPP agreementand links to the recently released sections of the document.
Finally, the opportunity to examine the particulars allows for citingspecifics. What are you supposed to believe, your own evaluation of theterms or the Summary of the Trans-Pacific Partnership Agreementprovided by the government?
Two sections prove enlightening. Start out with the TPP IntellectualProperty Chapter is “A Disaster for Global Health” and read the ExpertAnalysis: “Pharmaceutical Provisions in the TPP” (PDF, HTML).
•Patents for new uses and new methods of using existing products (Article QQ.E.1.2, p. 17);
•A low inventiveness threshold – potentially preventing countries fromtightening the criteria for granting patents (Footnote 33, p. 17);
•Patent term extensions to compensate for delays in granting patents(Article QQ.E.12, p. 20) and delays in marketing approval (ArticleQQ.E.14, p. 22);
•Data protection for small molecule drugs – at least 5 years for newpharmaceutical products plus 3 years for new indications, formulationsor methods of administration (Article QQ.E.16, p. 23-24);
•Patent linkage provisions likely to result in delays in marketing approval for generic drugs (Article QQ.E.17); and
•Market exclusivity for biologics, provided through one of two options:at least 8 years of data protection, or at least 5 years of dataprotection and other measures to “deliver a comparable outcome in themarket” (Article QQ.E.20, p. 25-26).
Oh, woe, is me. It sounds like Big Pharma has just spliced togethersome cartel genes that will extend their longevity as profit centers forthe management of diseases that never attempt to find actual cures.
The Washington Examiner reports in Why everybody hates the drug deal in the trade pact.
“The White House’s last-minute compromise on drug copyrightprotections in a huge trade agreement appears to have pleased nobody,with liberals, conservatives, patient groups and the industry allcriticizing the deal.”
“It is a giveaway to Big Pharma, which wants to lock cheaper genericsout of the market for eight years,” said Rep. Rosa DeLauro, D-Conn., aleading trade skeptic. “This will result in more expensive medicines, aswell as slower progress toward medical breakthroughs.”
What is found in the TPP talks is a precipitous pattern ofcorporatist protectionism over the beneficial interests of the consumer.So much for the lofty medicine, prescribed as “Free Trade”, as a curefor a healthier future.
In actuality Trans-Pacific Partnership could pose risk to public healthcare, leaked draft shows that most of Asian countries are being pushed into accepting the U.S. medical pharmacological model.
“The US was initially seeking 12 years of data exclusivity onbiologics, and they have now backed down to eight years in this draft,which they’re selling as a big concession and as a new flexibility,”said Gleeson, who is also a spokeswoman for the Public HealthAssociation of Australia.
“But eight years is much longer than the current protection period in all TPP countries except for Japan, Canada and the US.”
The next section has received far more attention. What will theinternet look like if all the provisions are implemented to penalize andeven criminalize fair use news reporting?
The International Business Times points out the legal jeopardy andcensorship implications encoded in the language of the agreement.